Trials / Suspended
SuspendedNCT00460278
Study of XL418 in Adults With Solid Tumors
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL418 Administered Orally Daily to Subjects With Solid Tumors
- Status
- Suspended
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 63 (estimated)
- Sponsor
- Exelixis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of XL418 in subjects with solid tumors. XL418 is a new chemical entity that inhibits a spectrum of targets, including Akt and p70S6K, that mediate PI3 Kinase / PTEN signaling.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XL418 |
Timeline
- Start date
- 2007-04-01
- First posted
- 2007-04-13
- Last updated
- 2008-06-04
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00460278. Inclusion in this directory is not an endorsement.